Apoorva Mandavilli

Founding Editor-in-Chief
Spectrum

Apoorva Mandavilli created Spectrum as an authoritative news source for scientists interested in autism. As editor-in-chief, she oversees Spectrum’s operations. 

Before launching Spectrum, Apoorva was senior news editor at Nature Medicine. She also worked as U.S. news editor at BioMedNet, health editor at About.com and was a newspaper and radio reporter. Her work has been featured in The New York TimesThe New Yorker online, The Atlantic, Slate and Popular Science, among others. Her article for Spectrum,The Lost Girls,” won first place in its category in the 2015 Association of Health Care Journalism Awards for Excellence, and is included in the 2016 “Best American Science & Nature Writing” anthology. Another article for the site, on electroconvulsive therapy, also won first place in its category in the 2016 Association of Health Care Journalism Awards for Excellence.

Apoorva has an M.S. in biochemistry from the University of Wisconsin-Madison and an M.A. in science journalism from New York University.

From this contributor

Explore more from The Transmitter

Headshots of Yale researchers Yong-Hui Jiang and Jiangbing Zhou.

Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions

Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.

By Natalia Mesa
3 June 2026 | 11 min read

What counts as a ‘naturalistic’ behavior?

Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.

By Paul Middlebrooks
3 June 2026 | 1 min read
Research image of brain cells involved with Amyotrophic lateral sclerosis (ALS) illuminated through genetic tools

Allen Institute sets sights on treatments for five brain diseases

The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.

By Calli McMurray
2 June 2026 | 5 min read